Carsten Niemann

Altered pathways as a biomarker for disease outcomes in CLL

The evolving CLL treatment paradigm

Machine learning to identify CLL patients at high risk of infection

Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy

Understanding risk factors for Ritcher’s transformation: addressing the unmet need

Death from infection: reducing the risk in patients with CLL

Promising results from the HOVON-141 trial for CLL

PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?

How to treat a previously treated CLL patient

Use of novel algorithms based on pattern recognition to identify patients in need of CLL treatment

What we are learning about CLL treatments and the microenvironment

Guidance on how to prevent infections in patients with CLL

Upcoming CLL trials on treatment options